UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT on Rite Aid Corporation on Weak March Sales

Loading...
Loading...
In a report published Friday, Goldman Sachs analyst Matthew J. Fassler reiterated a Neutral rating on Rite Aid Corporation
RAD
, but slightly lowered the price target from $1.85 to $1.75. In the report, Fassler noted, “RAD reported March sales including pharmacy volume that were a tad light, partially offset by better front-end trends, on the shift of Easter selling days into March and some underlying improvement. Slower prescription growth was inevitable – and widely understood – on tougher compares associated with cycling the capture of WAG/ESRX customers a year ago, though the degree of slowing in same-store script volumes still surprised us to the downside. Year ago compares become significantly tougher in April, and more challenging still in the summer months, peaking in October. As such, we believe the set-up for RAD over the balance of this year is difficult.” Rite Aid Corporation closed on Thursday at $1.72.
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman Sachs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...